"uuid:ID","rationale","versionIdentifier","id","instanceType"
"16493871-c187-431c-829b-ba2dfa3f8332","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion_1","StudyVersion"
